PDUFA date of March 27, 2025 for CARDAMYST™ (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT)- Commercial capabilities ...

It started with the odd sensation of feeling off-balance and stopped me in my tracks. I put those initial woozy moments down ...

A college student gets over the flu, but two weeks later feels winded after climbing stairs and complains of abdominal pain. What caused it?

Eculizumab biosimilar Elizaria demonstrates long-term safety and efficacy comparable with the reference product Soliris in ...

PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT targe ...

NYSE:BSX) Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation ...

Recent research shows the incredible success of radiofrequency ablation in treating AFib, offering renewed hope for patients.

Cardiac ablation has emerged as a transformative medical procedure for patients struggling with irregular heart rhythms particularly atrial fibrillation AFib By targeting and eliminating problematic a ...

The power, fuel efficiency, and longevity of an engine will heavily depend on the fuel that’s being delivered. Furthermore, an engine’s efficiency is dependent on a precisely calculated air-to ...

EGPA is rare, with an annual incidence of 1 per million, with a mean age of onset of 40‐60 years ... She reported dyspnea on exertion for 8 months prior, and more recently paroxysmal nocturnal dyspnea ...

In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ustekinumab ...